These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21712090)

  • 1. Clinical applications of non-antibacterial tetracyclines. Part II.
    Golub LM; Greenwald RA
    Pharmacol Res; 2011 Dec; 64(6):549-50. PubMed ID: 21712090
    [No Abstract]   [Full Text] [Related]  

  • 2. A new face for old antibiotics: tetracyclines in treatment of amyloidoses.
    Stoilova T; Colombo L; Forloni G; Tagliavini F; Salmona M
    J Med Chem; 2013 Aug; 56(15):5987-6006. PubMed ID: 23611039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases.
    Castro MM; Kandasamy AD; Youssef N; Schulz R
    Pharmacol Res; 2011 Dec; 64(6):551-60. PubMed ID: 21689755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease.
    Bench TJ; Jeremias A; Brown DL
    Pharmacol Res; 2011 Dec; 64(6):561-6. PubMed ID: 21624471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-antibiotic properties of tetracyclines and their clinical application in dermatology.
    Perret LJ; Tait CP
    Australas J Dermatol; 2014 May; 55(2):111-8. PubMed ID: 23808657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory activity of tetracyclines.
    Webster G; Del Rosso JQ
    Dermatol Clin; 2007 Apr; 25(2):133-5, v. PubMed ID: 17430750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New uses for tetracyclines.
    J Am Dent Assoc; 1997 Jul; 128(7):822, 826. PubMed ID: 9231598
    [No Abstract]   [Full Text] [Related]  

  • 8. [Nonantimicrobial effects of tetracyclines].
    García-Alvarez L; Oteo JA
    Rev Esp Quimioter; 2010 Mar; 23(1):4-11. PubMed ID: 20232018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation.
    Gu Y; Lee HM; Sorsa T; Salminen A; Ryan ME; Slepian MJ; Golub LM
    Pharmacol Res; 2011 Dec; 64(6):573-9. PubMed ID: 21771657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical applications of non-antimicrobial tetracyclines in dermatology.
    Monk E; Shalita A; Siegel DM
    Pharmacol Res; 2011 Feb; 63(2):130-45. PubMed ID: 20937386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The road forward: the scientific basis for tetracycline treatment of arthritic disorders.
    Greenwald RA
    Pharmacol Res; 2011 Dec; 64(6):610-3. PubMed ID: 21723947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Jack of all trades: pleiotropy and the application of chemically modified tetracycline-3 in sepsis and the acute respiratory distress syndrome (ARDS).
    Roy SK; Kendrick D; Sadowitz BD; Gatto L; Snyder K; Satalin JM; Golub LM; Nieman G
    Pharmacol Res; 2011 Dec; 64(6):580-9. PubMed ID: 21767646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of matrix metalloproteinase activities in periodontitis as a treatment strategy.
    Ryan ME; Golub LM
    Periodontol 2000; 2000 Oct; 24():226-38. PubMed ID: 11276869
    [No Abstract]   [Full Text] [Related]  

  • 14. The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease.
    Federici TJ
    Pharmacol Res; 2011 Dec; 64(6):614-23. PubMed ID: 21843641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines.
    Ramamurthy NS; Rifkin BR; Greenwald RA; Xu JW; Liu Y; Turner G; Golub LM; Vernillo AT
    J Periodontol; 2002 Jul; 73(7):726-34. PubMed ID: 12146531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-inflammatory effects of tetracyclines.
    Weinberg JM
    Cutis; 2005 Apr; 75(4 Suppl):6-11. PubMed ID: 15916224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction and background.
    Golub LM
    Pharmacol Res; 2011 Feb; 63(2):99-101. PubMed ID: 20937387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of matrix metalloproteinase inhibitors in cancer therapy.
    Purcell WT; Rudek MA; Hidalgo M
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1189-227. PubMed ID: 12512389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxin-induced periodontal breakdown in rats.
    Llavaneras A; Ramamurthy NS; Heikkilä P; Teronen O; Salo T; Rifkin BR; Ryan ME; Golub LM; Sorsa T
    J Periodontol; 2001 Aug; 72(8):1069-77. PubMed ID: 11525440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How do tetracyclines work?
    Ryan ME; Ashley RA
    Adv Dent Res; 1998 Nov; 12(2):149-51. PubMed ID: 9972140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.